1\) to test HDL function comprehensively in healthy and diseased individuals; 2) to evaluate if this test correlates with cardiovascular risk, independent of traditional risk factors; 3) and to differentiate effects of lipid-modifying or antiatherosclerotic drugs on HDL function and composition
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
58
The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Division of Cardiology, Department of Internal Medicine,
Seoul, South Korea
Cholesterol efflux capacity (%)
\[3H-cholesterol (µCi) in medium containing HDL/(3H-cholesterol {µCi} in medium containing HDL+µCi of 3H-cholesterol {µCi} in cells)\] x 100
Time frame: Change of HDL functions from baseline to 8 weeks
Endothelial NO production (Arbitrary unit)
measured with nitrate assay kit and expressed as relative amount compared to control (no HDL treatment sample)
Time frame: up to 8 weeks
VCAM-1 expression (Arbitrary unit)
western blotting of VCAM-1 protein and expressed as relative amount compared to control (no HDL treatment sample)
Time frame: up to 8 weeks
ROS generation (Arbitrary unit)
fluorescence intensity measurement using dichlorodihydrofluorescein diacetate and expressed as relative amount compared to control (no HDL treatment sample)
Time frame: up to 8 weeks
ApoA-I
quantitation of intensity of western blot and expresses as relative amount to control (no HDL treatment sample)
Time frame: Change of HDL associated proteins from each patient at baseline and at 8 weeks
ApoA-II
quantitation of intensity of western blot and expresses as relative amount to control (no HDL treatment sample)
Time frame: Change of HDL associated proteins from each patient at baseline and at 8 weeks
ApoC-I
quantitation of intensity of western blot and expresses as relative amount to control (no HDL treatment sample)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Time frame: Change of HDL associated proteins from each patient at baseline and at 8 weeks
ApoC-II
quantitation of intensity of western blot and expresses as relative amount to control (no HDL treatment sample)
Time frame: Change of HDL associated proteins from each patient at baseline and at 8 weeks
ApoC-III
quantitation of intensity of western blot and expresses as relative amount to control (no HDL treatment sample)
Time frame: Change of HDL associated proteins from each patient at baseline and at 8 weeks